& Zabielski, P
at 1-833-Wegovy-1 Marketed by: Novo Nordisk Inc
Current weight trend and prior weight loss attempts (what worked, what failed, and why) Full medication and supplement review (to reduce interactions and avoid avoidable side effects) Medical history that changes candidacy (GI disease, gallbladder history, pancreatitis risk factors, endocrine history) Pregnancy plans and contraception considerations when applicable Eating patterns (especially late-night eating, high-fat meals, alcohol intake) Sleep quality and stress load (often overlooked, but clinically relevant) What we avoid: prescribing based on a quick questionnaire and a number on a scale
NeuroReport 12(6):12931296
Adults with type 2 diabetes (T2DM) initiating GLP-1 RAs or DPP-4is between January 1, 2018, and December 31, 2022, were identified, excluding prior users of either class
The evidence for sermorelin is stronger than for most longevity peptides